FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2265380508> ?p ?o ?g. }

• W2265380508 abstract "Dihydroartemisinin-piperaquine (DHA-PQ) is one of five WHO recommended artemisinin combination therapy (ACT) for the treatment of uncomplicated malaria. However, little was known on its post-registration safety and effectiveness in sub-Saharan Africa. DHA-PQ provides a long post-treatment prophylactic effect against re-infection; however, new infections have been reported within a few weeks of treatment, especially in children. This paper reports the clinical outcomes following administration of DHQ-PQ in real-life conditions in public health facilities in Burkina Faso, Ghana, Mozambique, and Tanzania for the treatment of confirmed uncomplicated malaria. An observational, non-comparative, longitudinal study was conducted on 10,591 patients with confirmed uncomplicated malaria visiting public health facilities within seven health and demographic surveillance system sites in four African countries (Ghana, Tanzania, Burkina Faso, Mozambique) between September 2013 and April 2014. Patients were treated with DHA-PQ based on body weight and followed up for 28 days to assess the clinical outcome. A nested cohort of 1002 was intensely followed up. Clinical outcome was assessed using the proportion of patients who reported signs and symptoms of malaria after completing 3 days of treatment. A total of 11,097 patients were screened with 11,017 enrolled, 94 were lost to follow-up, 332 withdrew and 10,591 (96.1 %) patients aged 6 months–85 years met protocol requirements for analysis. Females were 52.8 and 48.5 % were <5 years of age. Malaria was diagnosed by microscopy and rapid diagnostic test in 69.8 % and 29.9 %, respectively. At day 28, the unadjusted risk of recurrent symptomatic parasitaemia was 0.5 % (51/10,591). Most of the recurrent symptomatic malaria patients (76 %) were children <5 years. The mean haemoglobin level decreased from 10.6 g/dl on day 1 to 10.2 g/dl on day 7. There was no significant renal impairment in the nested cohort during the first 7 days of follow-up with minimal non-clinically significant changes noted in the liver enzymes. DHA-PQ was effective and well tolerated in the treatment of uncomplicated malaria and provides an excellent alternative first-line ACT in sub-Saharan Africa." @default.
• W2265380508 created "2016-06-24" @default.
• W2265380508 creator A5001123545 @default.
• W2265380508 creator A5002994916 @default.
• W2265380508 creator A5010063678 @default.
• W2265380508 creator A5010966506 @default.
• W2265380508 creator A5014052148 @default.
• W2265380508 creator A5015249566 @default.
• W2265380508 creator A5022789874 @default.
• W2265380508 creator A5024909046 @default.
• W2265380508 creator A5027526478 @default.
• W2265380508 creator A5029353419 @default.
• W2265380508 creator A5032284171 @default.
• W2265380508 creator A5032318122 @default.
• W2265380508 creator A5033436437 @default.
• W2265380508 creator A5042463629 @default.
• W2265380508 creator A5043650852 @default.
• W2265380508 creator A5048147548 @default.
• W2265380508 creator A5049068779 @default.
• W2265380508 creator A5053343319 @default.
• W2265380508 creator A5053573268 @default.
• W2265380508 creator A5069437397 @default.
• W2265380508 creator A5069843611 @default.
• W2265380508 creator A5074012686 @default.
• W2265380508 date "2016-01-27" @default.
• W2265380508 modified "2023-10-15" @default.
• W2265380508 title "Treatment outcomes in a safety observational study of dihydroartemisinin/piperaquine (Eurartesim®) in the treatment of uncomplicated malaria at public health facilities in four African countries" @default.
• W2265380508 cites W1275343739 @default.
• W2265380508 cites W1970856471 @default.
• W2265380508 cites W1992510231 @default.
• W2265380508 cites W2023687237 @default.
• W2265380508 cites W2033755024 @default.
• W2265380508 cites W2048834380 @default.
• W2265380508 cites W2058689460 @default.
• W2265380508 cites W2082480743 @default.
• W2265380508 cites W2100206749 @default.
• W2265380508 cites W2106346927 @default.
• W2265380508 cites W2108216869 @default.
• W2265380508 cites W2111813303 @default.
• W2265380508 cites W2112658233 @default.
• W2265380508 cites W2115398829 @default.
• W2265380508 cites W2120091748 @default.
• W2265380508 cites W2123133638 @default.
• W2265380508 cites W2131274291 @default.
• W2265380508 cites W2134683647 @default.
• W2265380508 cites W2139242164 @default.
• W2265380508 cites W2142803342 @default.
• W2265380508 cites W2149705826 @default.
• W2265380508 cites W2155629163 @default.
• W2265380508 cites W2156872999 @default.
• W2265380508 cites W2157261068 @default.
• W2265380508 cites W2165895488 @default.
• W2265380508 cites W2168604498 @default.
• W2265380508 cites W3011293449 @default.
• W2265380508 cites W3144231438 @default.
• W2265380508 cites W4232252810 @default.
• W2265380508 doi "https://doi.org/10.1186/s12936-016-1099-7" @default.
• W2265380508 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4729128" @default.
• W2265380508 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26818128" @default.
• W2265380508 hasPublicationYear "2016" @default.
• W2265380508 type Work @default.
• W2265380508 sameAs 2265380508 @default.
• W2265380508 citedByCount "23" @default.
• W2265380508 countsByYear W22653805082016 @default.
• W2265380508 countsByYear W22653805082017 @default.
• W2265380508 countsByYear W22653805082018 @default.
• W2265380508 countsByYear W22653805082019 @default.
• W2265380508 countsByYear W22653805082020 @default.
• W2265380508 countsByYear W22653805082021 @default.
• W2265380508 countsByYear W22653805082023 @default.
• W2265380508 crossrefType "journal-article" @default.
• W2265380508 hasAuthorship W2265380508A5001123545 @default.
• W2265380508 hasAuthorship W2265380508A5002994916 @default.
• W2265380508 hasAuthorship W2265380508A5010063678 @default.
• W2265380508 hasAuthorship W2265380508A5010966506 @default.
• W2265380508 hasAuthorship W2265380508A5014052148 @default.
• W2265380508 hasAuthorship W2265380508A5015249566 @default.
• W2265380508 hasAuthorship W2265380508A5022789874 @default.
• W2265380508 hasAuthorship W2265380508A5024909046 @default.
• W2265380508 hasAuthorship W2265380508A5027526478 @default.
• W2265380508 hasAuthorship W2265380508A5029353419 @default.
• W2265380508 hasAuthorship W2265380508A5032284171 @default.
• W2265380508 hasAuthorship W2265380508A5032318122 @default.
• W2265380508 hasAuthorship W2265380508A5033436437 @default.
• W2265380508 hasAuthorship W2265380508A5042463629 @default.
• W2265380508 hasAuthorship W2265380508A5043650852 @default.
• W2265380508 hasAuthorship W2265380508A5048147548 @default.
• W2265380508 hasAuthorship W2265380508A5049068779 @default.
• W2265380508 hasAuthorship W2265380508A5053343319 @default.
• W2265380508 hasAuthorship W2265380508A5053573268 @default.
• W2265380508 hasAuthorship W2265380508A5069437397 @default.
• W2265380508 hasAuthorship W2265380508A5069843611 @default.
• W2265380508 hasAuthorship W2265380508A5074012686 @default.
• W2265380508 hasBestOaLocation W22653805081 @default.
• W2265380508 hasConcept C126322002 @default.
• W2265380508 hasConcept C138816342 @default.
• W2265380508 hasConcept C142724271 @default.
• W2265380508 hasConcept C185032368 @default.
• W2265380508 hasConcept C187212893 @default.
• W2265380508 hasConcept C201903717 @default.

• next